Star analyst Ives: Bullish on Apple (AAPL.US) up to $400, AI strategy may increase valuation by $75 per share
Ives has given Apple stock an "outperform" rating, with a target price of $400.
According to the Zhihu Finance APP, star tech analyst Dan Ives stated that Apple (AAPL.US)'s AI strategy could increase the company's valuation by about $75 per share, as the company seeks to leverage AI to drive device upgrades and boost service revenue. Ives rates Apple stock as "Outperform" with a target price of $400.
Ives noted in his report: "Apple is entering a new phase in the development of its ecosystem, where AI tightly integrates hardware, software, and services, not only driving device upgrades and improving per-user pricing, but also leading the next stage of its growth strategy." Given Apple's large user base, Ives estimates that AI-related revenue could eventually account for more than 15% of its service revenue.
The analyst said that Apple is focused on integrating AI into its products while emphasizing privacy and on-device processing, which could help make the technology a part of consumers' daily lives. He also expects that AI will create new opportunities in health, fitness, finance, and gaming sectors, with developers playing a key role in building these services.
Ives expects the iPhone 18 upgrade cycle to support Apple in the coming quarters. He estimates that about 375 million iPhones have not been upgraded for more than four years, representing a large potential pool of buyers.
Ives also expects that Apple's foldable-screen iPhone Duo will bring additional demand, estimating that sales will reach about 10 million units over the next few quarters.
Tipranks data shows that Wall Street analysts are clearly divided on Apple. Among the 31 analysts covering the stock, 16 give a "Buy" rating, 11 give a "Hold" rating, and 4 give a "Sell" rating. The consensus rating is "Moderate Buy," with an average target price of $337.51, slightly lower than the latest closing price.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
